Viracta | Investor Relations

Month Year

Investor Alerts

Jul 6, 2021

Viracta Therapeutics Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer and Key Additions to Management Team

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Ayman El-Guindy, Ph.D., as Chief Scientific...
Jun 28, 2021

Viracta Therapeutics Announces its Addition to the Russell 2000® Index and other FTSE Russell Indexes

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has been added as a member of the small-cap Russell 2000®...
Jun 1, 2021

Viracta Therapeutics Announces the Initiation of NAVAL-1, a Global Pivotal Trial for the Treatment of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma

Now open for enrollment, NAVAL-1 is a multicenter basket trial with an adaptive Simon 2-stage design

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the initiation of NAVAL-1 (Nanatinostat in Combination with...
May 27, 2021

Viracta Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the Jefferies...
May 18, 2021

Viracta Therapeutics to Host Key Opinion Leader Webinar

Virtual KOL event to focus on the unmet medical need in relapsed/refractory EBV-positive lymphoma and the design of NAVAL-1, a global pivotal trial

Viracta Therapeutics, Inc. (Nasdaq: VIRX) (Viracta), a precision oncology company targeting virus-associated malignancies, will host a key opinion leader (KOL) webinar on nanatinostat and...
May 12, 2021

Viracta Therapeutics Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates

NAVAL-1, a global pivotal trial for the treatment of relapsed/refractory EBV-positive lymphoma is on track to be initiated in Q2 2021

Viracta Therapeutics, Inc. (Nasdaq: VIRX) (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced financial results for the first quarter of...
Apr 8, 2021

Viracta Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that Company management will present at the 20th Annual...
Mar 23, 2021

Viracta and XOMA Announce Multi-License Milestone and Royalty Monetization Transaction

Viracta to Receive $13.5 Million Upfront Cash Payment

Viracta Therapeutics, Inc. (Nasdaq: VIRX), and XOMA Corporation (NASDAQ: XOMA) announced today XOMA has purchased the potential future milestones and royalties associated with existing licenses...
- Photos 2
Mar 11, 2021

Viracta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Dr. Ivor Royston, President and Chief Executive Officer of...
Mar 4, 2021

Viracta Therapeutics Strengthens Company Leadership with New Appointments to the Board of Directors and Management Team

Stephen Rubino, Ph.D., MBA and Barry J. Simon, M.D. appointed to the Board of Directors

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that it has strengthened its leadership team with the appointments...
Mar 3, 2021

Viracta Therapeutics to Participate at H.C. Wainwright Global Life Sciences Conference

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Viracta will participate at the H.C. Wainwright Global Life...
Feb 24, 2021

Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement

Shares of Viracta to commence trading on the Nasdaq Global Select Market on February 25, 2021 under ticker symbol 'VIRX'

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the closing of its merger with Sunesis Pharmaceuticals, Inc....
Feb 16, 2021

Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma

Resulting patent to extend Viracta's intellectual property protection into at least 2040

Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has...
Feb 11, 2021

Viracta Therapeutics to Participate in Upcoming Virtual Investor Conferences

Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the Company will participate in the upcoming LifeSci...
Dec 7, 2020

Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End of Phase 2 Meeting with the FDA

Promising data show complete responses observed across multiple subtypes of Epstein-Barr virus positive (EBV+) lymphoma; preliminary ORR/CR of 80%/40% in T/NK-NHL and 66%/33% in DLBCL

PR Newswire, San Diego, December 7, 2020 - Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced recent...
Nov 30, 2020

Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement

Merger to create Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignancies

SOUTH SAN FRANCISCO and SAN DIEGO, Calif., November 30, 2020 (GLOBE NEWSWIRE) - Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) and Viracta Therapeutics, Inc., a privately held precision oncology...
Oct 8, 2020

Viracta Therapeutics to Present at the Solebury Trout Fall Private Company Showcase 2020

PR Newswire, San Diego, October 8, 2020 - Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston,...
Sep 14, 2020

Viracta Therapeutics Announces Appointment of Roger J. Pomerantz, MD, FACP as Chairman of the Board of Directors

Viracta Therapeutics, Inc. ("Viracta" or the "Company"), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Roger J. Pomerantz, MD, FACP, as...
Sep 9, 2020

Viracta Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of...
Jul 20, 2020

Viracta Announces the Appointment of Mark A. McCamish, MD, PhD as Strategic Advisor

Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, today announced that Mark A. McCamish, MD, PhD, has joined Viracta as a...
Jul 14, 2020

Viracta Therapeutics Announces Appointment of Roger J. Pomerantz, MD to its Board of Directors

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that Roger J. Pomerantz, MD, FACP, has been appointed to its Board of Directors....
Jul 9, 2020

Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering its Combination Product Candidate for the Treatment of Viral or Virally-Induced Conditions

Resulting patent to extend Viracta's intellectual property protection

Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance...
Jun 24, 2020

Viracta Therapeutics Announces Orphan Drug Designation Granted for the Treatment of T-cell Lymphoma

PR Newswire, San Diego, June 24, 2020 - Viracta Therapeutics, Inc., a precision oncology company targeting virus-associated malignancies, today announced that its Phase 2 all-oral combination...
May 28, 2020

Viracta Therapeutics to Host Key Opinion Leader Call on the Treatment of EBV-Associated Lymphoma

Call Will Feature Ronald Levy, MD (Stanford University) and Pierluigi Porcu, MD (Thomas Jefferson University)

SAN DIEGO, May 28, 2020 - Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that it will host a key opinion leader...
Apr 8, 2020

Viracta Receives Welcome FDA Guidance at Type C Meeting for the Treatment of EBV-Associated Lymphomas

Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that the Company recently held a collaborative and productive...

Show per page

News Releases

Explore

Contact

Follow

Legal